Scientific Sessions
  • #AHA22
  • Virtual Experience Access
  • Sessions Posters
  • Late-Breaking Science
  • Daily Coverage
  • Industry Highlights
  • Featured Exhibitors
  • Program
  • Previews
Topics
  • Late-Breaking Science
  • Daily Coverage
  • Industry Highlights
  • Featured Exhibitors
  • Program
  • Previews
Resources
  • #AHA22
  • Virtual Experience Access
  • Sessions Posters
User Tools
  • Privacy Policy
  • Terms & Conditions
  • Accessibility Statement
Twitter iconFacebook iconInstagram iconYouTube iconPinterest iconLinkedIn icon
Nov 4th, 2021

Video: Plan your schedule now for #AHA21

Be sure to start your calendar of events for Scientific Sessions with this lineup of groundbreaking late-breaking science results.


LBS.01 | Valves, Veins and New Viewpoints in Cardiothoracic Surgery | 9:30-10:30 a.m. EST, Saturday, Nov. 13

  • Aortic Valve Replacement Versus Watchful Waiting in Asymptomatic Severe Aortic Stenosis: The Avatar Trial (AVATAR)
  • Evaluating the Benefit of Concomitant Tricuspid Repair During Mitral Valve Surgery
  • A Randomized Study of Early Versus Standard Coronary Artery Bypass Surgery Among Patients Presenting With Acute Coronary Syndromes Treated With Ticagrelor (RAPID CABG)
  • Efficacy and Safety of an External Support Device for Saphenous Vein Coronary Bypass Grafts: The VEST Trial (VEST) 

LBS.02 | Hypertension: Local, Global and Pandemic Impacts | 3-4 p.m. EST, Saturday, Nov. 13

  • A Remotely Delivered Hypertension and Lipid Program in 10,000 Patients Across a Diverse Health Care Network
  • Disruption in Blood Pressure Control With the COVID-19 Pandemic: A Study of 24 U.S. Health Systems in the PCORnet Blood Pressure Control Laboratory (BP Track)
  • A Cluster Randomized Trial of a Village Doctor-Led Intervention on Blood Pressure Control: China Rural Hypertension Control Project (CRHCP)

LBS.03 | Prevention to Intervention in Atrial Arrhythmias | 8-9 a.m. EST, Sunday, Nov. 14

  • The Coffee and Real-Time Atrial and Ventricular Ectopy (CRAVE) Trial (CRAVE)
  • Dabigatran Versus Warfarin on Cognitive Outcomes in Nonvalvular Atrial Fibrillation: Results of the GIRAF Trial. (GIRAF)
  • Posterior Left Pericardiotomy Reduces Postoperative Atrial Fibrillation After Cardiac Surgery (PALACS)
  • Outcomes of Adjunctive Left Atrial Appendage Ligation Utilizing the LARIAT Compared to Pulmonary Vein Antral Isolation Alone: The AMAZE Trial (AMAZE)

LBS.04 | Information Overload? Striving to Improve Care Delivery Through Digital Health and Automated Data | 2:45-3:45 p.m. EST, Sunday, Nov. 14

  • Risk Evaluation and its Impact on Clinical Decision-Making and Outcomes in Heart Failure: The REVeAL-HF Trial (REVeAL-HF)
  • Detection of Atrial Fibrillation in a Large Population Using Wearable Devices: The Fitbit Heart Study         
  • Testing Individualized Triggers of Atrial Fibrillation: A Randomized Controlled Trial (I-STOP-AFib)

LBS.05 | Building on the Foundations of Treatment: Advances in Heart Failure Therapy | 4-5 p.m. EST, Sunday, Nov. 14

  • Empagliflozin in Heart Failure With a Preserved Ejection Fraction ≥50% — Results From the EMPEROR-Preserved Clinical Trial   (EMPEROR-Preserved)
  • The Canagliflozin Impact on Health Status, Quality of Life and Functional Status in Heart Failure (CHIEF-HF) Clinical Trial (CHIEF-HF)
  • Efficacy and Safety of Empagliflozin in Hospitalized Heart Failure Patients: Main Results From the EMPULSE Trial (EMPULSE)
  • Randomized Trial of Targeted Transendocardial Delivery of Mesenchymal Precursor Cells in High-Risk Chronic Heart Failure Patients With Reduced Ejection Fraction (DREAM-HF)

LBS.06 | Fish Oil, Cocoa and Cholesterol: Recipes for CVD Prevention? | 8-9 a.m. EST, Monday, Nov. 15

  • Icosapent Ethyl Versus Placebo in Outpatients With COVID-19: The Main Results of PREPARE-IT 2 (PREPARE-IT 2)
  • The Clinical Safety, Pharmacokinetics and LDL-Cholesterol Lowering Efficacy of MK-0616, an Oral PCSK9 Inhibitor 

LBS.07 | New Drugs and New Drug Indications in Cardiovascular Disease | 11 a.m.-Noon EST, Monday, Nov. 15

  • Effects of Aspirin on Dementia and Cognitive Impairment in the ASCEND Trial (ASCEND)
  • P2y12 Inhibitors in Noncritically Ill Hospitalized Patients With Covid-19 (ACTIV-4A)
  • Effect Of Bentracimab on Platelet Inhibition and Hemostasis in Ticagrelor Patients With Uncontrolled Hemorrhage or Requiring Urgent Surgery in the REVERSE-IT (REVERSE-IT)
  • Milvexian for Prevention of Venous Thromboembolism After Elective Knee Arthroplasty: The AXIOMATIC-TKR Study (AXIOMATIC-TKR)
Interesting Stories
MiCare Path joins the AHA CHTI and will integrate AHA science-based
Sponsored by MiCare Path
MiCare Path joins the AHA CHTI and will integrate AHA science-based
Data-driven precision medicine
Sponsored by Tempus
Data-driven precision medicine
Modern Wearable Defibrillation
Sponsored by Kestra Medical Technologies
Modern Wearable Defibrillation
New Double Take Videos from NEJM
Sponsored by NEJM Group
New Double Take Videos from NEJM
More Content
Screenshot 2021 11 02 130142
Sponsored Content
Antiplatelet Therapy in Patients With Coronary Artery Disease and Acute Ischemic Stroke/Transient Ischemic Attack
Oct 4th, 2022
Getty Images 1180201381
Daily Coverage
Join the Scientific Sessions 2022 Scavenger Hunt
Aug 15th, 2022
Live Meeting Image
AHA21
Member Connect
Dec 13th, 2021
P104 Steven Botts Image
AHA21
Members Connect: ERG Governs Chromatin Accessibility in Aortic Endothelial Cells
Dec 13th, 2021
Pres Address Lloyd Jones2
AHA21
Watch: #AHA21 recap and look ahead
Nov 22nd, 2021
Getty Images 1301907602
AHA21
Mark your calendar for #AHA22
Nov 19th, 2021
Elaine Hylek, MD, MPH, and Bruno Caramelli, MD, PhD
AHA21
Trials’ results suggest advancements in treatment approaches for AF and insight on the cardiac effects of coffee consumption
Nov 19th, 2021
Lbs02 Group Blood Patel
AHA21
Update on local and global hypertension science
Nov 19th, 2021
Getty Images 1219980553 61849bc953192
AHA21
Read all about #AHA21 in your daily coverage
Nov 16th, 2021
(from left to right): Brahmajee K. Nallamothu, MD, MPH, FAHA, Rhoda Au, PhD, Seth Martin, MD, MHS, FAHA, and Andrea Beaton, MD, FAHA
AHA21
QCOR at Sessions: mHealth strategies could help treat CVD around the world
Nov 15th, 2021
(from left to right, top to bottom rows): Corey E. Ventetuolo, MD, MS, Magdi Yacoub, OM, FRS, Karen Joynt Maddox, MD, MPH, FAHA, Gregory Lewis, MD, Marco Guazzi, MD, PhD, FAHA, Ana Macumbi, MD, PhD, FESC, Mark T. Gladwin, MD, FAHA, and William Bain, MD
AHA21
The shifting profile of cardiopulmonary COVID-19 survivors
Nov 15th, 2021
(from left to right): Jonathan P. Piccini, MD, MHS, FAHA, and Steven A. Lubitz, MD, MPH, FAHA
AHA21
Late-Breaking Science: New information in cardiac disease
Nov 15th, 2021